On November 13, 2020, the FDA approved pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA approved test.
August 2020Read More
In late June, the FDA approved PHESGO™ (pertuzumab/ trastuzumab/ hyaluronidase-zzxf), a treatment that can be injected under the skin, to treat metastatic and...
September 2019Read More
The U.S. Food and Drug Administration (FDA) approved Piqray® for treating advanced breast cancer. Use the links below to learn more about the FDA approval and how...
New To Clinical Trials?
The idea of finding and entering a clinical trial can seem daunting. Here’s a Clinical Trials Primer to get you started.
Search Our Site
SEARCH OUR SITE
for past articles or specific information.